Scholar Rock: New Phase 2 TOPAZ Trial Data
Scholar Rock has recently issued a press release regarding New Phase 2 TOPAZ Trial Data.
The Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA.
- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months.
- These data indicate the potential for sustained improvement in quality-of-life measures for patients with symptomatic SMA and offer further evidence of possible durable effects of apitegromab
For more information, please consult the press release below.